Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of QL2108 vs Dupixent in Healthy Chinese Adults
NCT06614907Phase 1Completed
- Sponsor
- Qilu Pharmaceutical
- Start
- Aug 2024
- Primary completion
- Nov 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of QL2108 in atopic dermatitis (AD) (2 arms), sponsored by Qilu Pharmaceutical. Primary endpoint: Pharmacokinetics Endpoint. Started Aug 2024; status: completed.
02
Drugs
QL2108
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT06614907.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06614907.